Method for increasing general nonspecific resistance of mammal body

FIELD: medicine.

SUBSTANCE: invention refers to experimental biology and medicine. The method involves parenteral introduction of a protein preparation. Ceruloplasmin is used as said protein preparation. Ceruloplasmin is introduced intravenously in dosage 7.5 mg/kg of animal body weight, for the total course of 3 injections every second day.

EFFECT: method allows intensifying anti-oxidant protection of an animal body, stimulating hemopoietic and immunological processes, and thereby providing aquatation of protective adaptive responses.

1 ex


The invention relates to the field of experimental biology and medicine and can be used to improve the overall nonspecific resistance of the organism mammals in various pathological conditions associated with the development of peroxidation-antioxidant imbalance and severe disorders of the immune status.

The known method of increasing the compensatory capacity of mammals, consisting in the inhalation of a hypoxic gas mixture, alternating with the inhalation of atmospheric air. Used part of the exhaled air to re-inhalation, reduce the consumption of hypoxic gas mixture prior to the onset of a mammal difficulty breathing. Then increase the hypoxic gas mixture to reduce shortness of breath and support the flow of hypoxic gas mixtures to levels that can produce moderate difficulty breathing mammal (RF patent No. 2108814, CL AM 16/00. Publ. 20.04.1998 year).

However, the known method is technically complex and time-consuming in execution.

There is also known a method of increasing the resistance of the organism in the experiment, namely, that hold the intake of 0.7-1.0 ml of blood from a vein, filgrastim dose of 10 mg/kg incubated with the blood 45 minutes at 37°C. followed by reinfusion (RF patent No. 2278690, CL AC 38/17, OR 37/02. Publ. 27.06.2006 g).

The disadvantage of this method is the complexity and difficulty of execution (the need for blood sampling, followed by incubation with the drug filgrastim and maintaining the resulting mixture at a specific temperature for a certain time) and intravenous reinfuse the mixture.

Closest to the proposed by its technical essence is a way to increase non-specific resistance, including intramuscular injection of nonspecific immunoglobulin with an additional appointment for the oral administration of biologically active stimulant in the form of an aqueous solution of 7-8%concentration at a dose of 2.0-2.5 ml/kg weight of the animal within 10-15 days with an interval of 24 hours (patent RF №2305551, CL AC 36/28, AK 36/53, AK 36/484, OR 37/00. Publ. 10.09.2007 BC).

The disadvantage of the prototype is the fact that for its implementation, in addition to intramuscular (parenteral) administration of the protein preparation is required for further use of a biologically active multi-component stimulator comprising extracts of herbs and roots. In addition, this method is time-consuming to conduct (10-15 days).

The challenge which seeks the invention is to simplify the method and shortening to achieve a positive result in increased non-specific resistant the spine of the body.

The problem is solved in that way increase the overall nonspecific resistance of the organism mammals by injecting the protein preparation, used as a protein drug use "Ceruloplasmin", administered intravenously at a dose of 7.5 mg/kg animal body weight, General course of 3 injections a day.

"Ceruloplasmin" ("Ceruloplasminum") - multifunctional medicinal drug, which is a glycoprotein alpha-2-globulin fraction of blood. The drug is approved for medical use in the Russian Federation (on the main page. Drugs in Russia: a Handbook. - M.: Attraversare, 2006, SB-1180).

Empirically, the authors claimed invention found that a dose of ceruloplasmin, a component of 7.5 mg/kg animal body weight is optimal for achieving the desired effect on the increase of resistance due to the improvement of peroxidation-antioxidant imbalance.

Dose of less than 7.5 mg/kg (5.0 mg/kg) does not provide adequate effect for improving the overall nonspecific resistance of the organism, and the dose of 7.5 mg/kg (10 mg/kg) does not give an additional positive effect to received.

The General course of treatment consisting of 3 intravenous injection, carried out through the day, to achieve optimal therapeutic effect and improve the state is of peroxidation-antioxidant imbalance in conditions of experimental arthritis in rabbits, confirmed by the data of instrumental and laboratory methods of research.

The technical result consists in the normalization of peroxidation-antioxidant balance by correcting the insolvency element of the antioxidant enzyme system.

The proposed method is as follows.

Rabbit with experimental rheumatoid arthritis is fixed on the machine for laboratory animals. Before drug injection is treated with 5%solution of iodine. Introduction ceruloplasmin is carried out in the marginal vein of the ear slowly sterile syringe at a dose of 7.5 mg/kg animal body weight, General course of 3 injections carried out through the day. After manipulation of the injection is sealed bactericidal plaster.

The inventive method was tested on 38 rabbits breed "Chinchilla Russian"was in standard vivarium conditions with free access to food and water. All experiments on animals were conducted in accordance with the standards of the Ethics Committee and the Declaration of Helsinki 1983

Experimental animals were divided into 5 groups:

1st group (control) - 7 intact (healthy) rabbits;

Group 2 (comparison) - 9 rabbits with experimental rheumatoid arthritis without treatment;

Group 3 (experienced) - 7 rabbits with experimental rheumato denim arthritis, who underwent a course of intravenous injection of ceruloplasmin in a dose of 5.0 mg/kg animal body weight, General course of 3 injections carried out in a day;

4-I group (experienced) - 8 rabbits with experimental rheumatoid arthritis who received a course of intravenous injection of ceruloplasmin in a dose of 7.5 mg/kg animal body weight, General course of 3 injections carried out in a day;

5th group (experienced) - 7 rabbits with experimental rheumatoid arthritis who received a course of intravenous injection of ceruloplasmin in a dose of 10.0 mg/kg animal body weight, General course of 3 injections carried out through the day.

Example. Rabbit No. 17 weight 3.4 kg was formed experimental rheumatoid arthritis according to the method Pettipher E.R. et al., (1987). The formation of the model was confirmed by clinical, instrumental and laboratory methods of research.

On visual inspection of the animal sedentary compared with intact rabbits. He had a reduced appetite, weight was 3,220 kg

The amount of experienced joint increased almost 1.5 times compared with symmetric joint. Due to swelling and severe pain reaction rabbit not relied on this limb.

Thermal analysis confirmed arthritis of the right knee joint. Detected temperature reaction in the area of the right knee joint was manifested by the difference in temperature is between ur experienced and symmetric joint and 0.9°C.

Along with the described clinical and imaging patterns diseases detected changes in laboratory parameters. The rabbit had metabolic disorders, both General and local character.

There is a strong overall activity of the inflammatory process, manifested by reduced hemoglobin - 118,20 g/l at norm 124,30±0,80 g/l; the number of red blood cells - to 3.33·1012/l at the rate of 4.04±0,10·1012/l; EMAS - 7,40 mm/h at the rate of 2.8±0.20 mm/h and the total number of leukocytes - 10,14·109/l at the rate of 7.60±0,11·109/l, and their band - of 5.82% at the rate of 3.96±0,18% and segmented - 51,37% at the rate 42,60±0,81% forms. Lymphocytes constituted of 33.26% at the rate 47,80±0,84%; eosinophils - to 2.57% at the rate 1,49±0,10%; monocytes - to 4.62% at the rate 3,44±0,12%.

Increased activity of enzymes (alanine aminotransferase - 29,4 E at the rate of 24.8 E; aspartate aminotransferase - 53,6 E at the rate of 48.5 E;

gamma-glutamyltranspeptidase - 5,7 E at the rate of 4.2 (E) testified to the development of liver damage, and increased total protein content to 61.8 g/l at norm - 56,35 g/l and urea to 7.02 mmol/l at norm - 5,95 mmol/l was speaking about violations of protein metabolism and renal function, respectively.

Also was discovered peroxidation-antioxidant imbalance lies in the activation of processes of lipid peroxidation (malonic dialdehyde - 5,2 MK is ol/l at norm 3,59±0.15 µmol/l) and insolvency enzyme level of the antioxidant system of blood (ceruloplasmin - 22,14 $ with the norm 27,77±1,03$).

The rabbit had a significant increase in the concentration of lactate in the blood - 17,12 mmol/l at norm 10,86±0.15 mmol/l and the pH decrease blood - 7,32 at the rate 7,42±0,01, testified to the disruption of the acid-base balance.

There was a statistically significant tension immunopathological reactions, defined by elevated levels of circulating immune complexes in serum - $ 21,10 compared with normal values for intact animals - 13,00±1,56 $

The total or aggregate severity of metabolic disorders were assessed in terms of molecules of average weight - 0,312 eop the norm 0,236±0,002 EDEP

Described denominated metabolic disorders identified in animals with experimental rheumatoid arthritis were similar with similar changes in patients with rheumatoid arthritis, which led to a reduction in the overall nonspecific resistance of the organism in this pathology.

This rabbit therapy using medicinal product "ceruloplasmin, enter in the vein slowly at a dose of 7.5 mg/kg animal body weight, General course of 3 injections a day.

After the treatment there was an improvement in the General condition of the animal. It was noted decrease swelling and temperature experienced joint. is in original condition. Palpation of the joint painless. The improvement of clinical picture of the disease was also confirmed by the data of laboratory tests.

There was a positive trend in the results of laboratory indicators: increase in the level of haemoglobin up of 122.5 g/l and the number of erythrocytes up to 3.58·1012/l, a reduction of ESR to 3.7 mm/h, total number of leukocytes to 8.3·109/l, stab neutrophils to 4.4% and segmented neutrophils to 46.1 per cent, and the reduction of eosinophils to 2,19%, monocytes before 3,81% and an increase of lymphocytes to 39,14%.

There was also a reduction in the activity of enzymes (alanine aminotransferase to 26.8 E, aspartate aminotransferase to 50.4 E, gamma-glutamyltranspeptidase to 4.8 (E), total protein content up to 59.0 g/l and urea to 6.84 mmol/l in the serum of the animal.

Indicators peroxidation-antioxidant balance was also positive: reduction of malondialdehyde to 4.7 mmol/l and increased activity of ceruloplasmin to 24.8 $

This rabbit has been an improvement in the blood pH to 7.35, reduction of circulating immune complexes to 16.00 USD, the level of lactate to 15,80 mmol/l and a content of molecules of average weight to 0,278 EDEP

Thus, the proposed method can improve the overall nonspecific resistance of the organism in conditions of experimental rheumatoid is rcrit, accompanied by the development of peroxidation-antioxidant imbalance and impaired immune status, which is possible due to intravenous injection of ceruloplasmin. This drug, showing antioxidant and immunomodulatory properties, launches molecular mechanisms that ensure the activation of the protective and adaptive reactions. The latter is achieved by resolving insolvency antioxidant protection system of the body, stimulation of hematopoietic and immunological processes, as well as decrease the severity of the intoxication of the organism as a whole.

The way to increase overall nonspecific resistance of the organism mammals by injecting the protein preparation, characterized in that is used as a protein drug use "Ceruloplasmin", administered intravenously at a dose of 7.5 mg/kg animal body weight, General course of 3 injections a day.


Same patents:

FIELD: medicine.

SUBSTANCE: invention relates to field of medicine, namely to neurosurgery and tissue engineering of organs. Neuroendoprostetic system is obtained by perfusion of autologic cell composition into heterogeneous collagen-containing matrix for implantation with obtaining resilient-elastic cellular-biopolymeric biologically active mass. Biocomposition contains present in NaCl solution neutral stem cells (NSC), neuroglial sheathing cells (NGSC), endothelial cells with marker CD34+(EK) and purified mononuclear cells (MN). In carrying out reconstructive neurosurgical operation neuroendoprosthetic system is implanted into nervous tissue defect.

EFFECT: elaborated neuroprosthetic system allows to ensure stimulation of regeneration and growth of affected axons of nervous cells in carrying out reconstructive neurosurgical operations.

3 tbl, 2 dwg, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine and veterinary, in particular to blood diagnostics. Claimed is method of obtaining post-test leucoconcentrate, which includes functional test: in Ependorf type tube on 1.5 ml 0.05 ml of fresh heparinised blood is introduced, into the same tube introduced is 0.05 ml of 0.2% nitroblue tetrazolium (NBT) solution on phosphate salt buffer or 0.05 ml of suspension of particles for phagocytocis, after finishing functional test the following activities are performed: 1 ml of 3.5% acetic acid solution is added, thoroughly mixed, centrifuged for 5 minutes at 1500 revolutions per minute, supernatant liquid is removed, sediment is re-suspended in remaining liquid, and with even distribution is applied on microscope slide, after which it is dried and stained by any suitable method.

EFFECT: invention ensures improvement of functional properties of post-test leucoconcentrate.

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to experimental surgery, and can be used for correction of ischemic liver affection. For this purpose 2 hours before operation 5% mexicor solution in dose 10 mg/kg of weight is intravenously jet injected to experimental animal. After that one hour before operation actovegin in dose 10 mg/kg of weight is intravenously jet injected. During operation ischemia is created by temporal extracorporal portacaval shunting. In post-operation period each of preparations is introduced 1 time a day during 7 days. Interval between their introduction is 12 hours: mexicor is introduced at 8 o'clock, actovegin - at 20 o'clock.

EFFECT: method ensures reduction of reperfusion disorders, elongation of safe terms of liver exsanguination up to 30 minutes and prevention of massive hemorrhage in operations on this organ.

3 dwg, 4 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to vascular surgery, and can be used in treating chronic obliterating diseases of lower extremity arteries. That is ensured by introduction of thrombocyte-enriched autoplasma containing polypeptide growth factors into an involved extremity. Said introduction is ultrasound aided from two points in inguinal and popliteal regions in amount 100 ml for each with distributing along the deep artery of thigh and popliteal artery and in adjacent muscles.

EFFECT: method allows stimulating development of collateral blood flow in an ischemic limb and improving arterial inflow from proximal to distal regions.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to experimental medicine and concerns preparation of a cell transplantation material in myelosuppression. That is ensured by subcutaneous introduction to a laboratory animal of a recombinant granulocytic colony-stimulating factor (G-CSF) in dosage 125 mcg/kg once a day for 3 days. It is combined with intraperitoneal introduction of hyaluronidase in dosage 1000 SU/kg once a day for 2 days. Then mononuclear leukocyte fraction of peripheral blood is prepared, placed in a balanced nutrient medium containing 10-8 mol/ml of D-glucuronic acid, and incubated for 2 hours.

EFFECT: introduction of G-CSF and hyaluronidase in the developed dosage and regimen, in combination with incubation with D-glucuronic acid added provides higher therapeutic activity of the graft due to mononuclear growth in peripheral blood and better engrafting ability.

1 ex, 4 tbl

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particular to neurology, physiotherapy. The method includes cryomassage of lumbosacral spine and sinusoidal modulated current electrophoresis in the erect mode with paravertebral location of the electrodes. In addition, cryomassage affected limb is made. During cryomassage skin is cooled till +10 +12 °C. Exposure during 10 minutes in one area. In 30-40 minutes electrophoresis is made. For electrophoresis adgelona solution with a concentration of 10-12 mol/liter is used. For it a pad soaked in 5 ml of adgelona is placed under the electrode-cathode. For the used mode work I a frequency modulation (FM) is 100 Hz, and modulation depth (MD) is 50% and for III mode of work with FM is 80 Hz and MD is 50%. The duration of half-periods is 2 and 3 sec. Duration of implementation of each mode if work is 7 minutes. A course of treatment consists of 10-12 procedures carried out daily.

EFFECT: method prevents development of epidural and perineural fibrosis, reduces the treatment period and increases the duration of remission.

2 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: group of invention belongs to versions of pharmacologic composition designed for stimulation of cells' growth and regeneration and to methods of composition's manufacture. Composition contains lysate of peripheral blood leukocytes, stem and progenitor cells obtained from animal which preliminary undergone biopsy of those inner organs or skin, in which growth and regeneration must be stimulated. Another version of composition contains lysate of peripheral blood leucocites and/or stem and/or progenitor cells obtained from animal which preliminary undergone biopsy of those inner organs or skin, in which growth and regeneration must be stimulated. Peripheral blood leukocytes and/or stem and/or progenitor cells was preliminary cultivated with obtained by biopsy destroyed cells of inner organs or skin in which growth and regeneration must be stimulated. Versions of manufacture method include cells' acquisition followed by destruction.

EFFECT: invention provides improvement of regeneration process in affected organ.

14 cl, 2 tbl, 6 dwg, 7 ex

FIELD: chemistry; biochemistry.

SUBSTANCE: invention relates to biotechnology, in particular to obtaining cell populations of T-lymphocytes, and can be used in medicine. The method involves isolation a population of CD4+T-cells from peripheral blood of a patient and culturing the cells in a growth medium containing monoclonal antibodies to CD28 (anti-CD28) in amount of 0.5-10 mcg/ml and to CD3 (anti-CD3) in amount of 0.5-10 mcg/ml, TGF-beta 1 (1-50 ng per ml) and interleukin-2 (IL-2) in amount of 10-1000 units/ml. The obtained population of CD4+T-cells is used in a method of treating diseases characterised by pronounced reduction of amount and/or functional activity of regulatory T-cells.

EFFECT: invention enables obtaining of a population of lymphocytes rich in regulatory T-cells ex vivo.

2 cl, 8 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to oncology and can be used for treatment of pulmonary cancer. Essence of invention lies in the fact that before initiation of treatment an extracorporeal ray treatment of 300 ml of patient's blood in red diapason range with λ=0.67 mcm in continuous-wave mode during 3 minutes at maximum radiant power 17 mlW, radiation level w=3.06 J/cm2 is conducted. Then irradiated blood is incubated with cytostatic in therapeutic dose during 40 minutes at T=37°C, whereafter the irradiated blood with cytostatic is inserted to patient intravenously by drop infusion. During course of treatment three or four such procedures are conducted at three days interval, in total one or two courses of treatment at three weeks interval are conducted.

EFFECT: use of this invention enables to transfer patients with tumors of stage three or four into resectable condition by means of stimulating involution and regress of neoplastic deposits from lymphonodus at neoadjuvant therapy delivery of photo- modified autoblood.

2 ex

FIELD: medicine.

SUBSTANCE: to ensure optimal preparation of children to spinal operation is ensured by the preclinical analysis of iron metabolism parametres, detection of the latent iron deficiency to be corrected, and also making an individual autodonation program included acute normovolemic hemodilution. Two days before the first donation, iron preparations are introduced in a dose 1/2 of a daily dose to be continued with a complete dose during the whole preoperative and thereafter postoperative period. After donation, the exfused autoblood volume is compensated in the equivalent volume with a plasma substitute solutions: crystalloids - 6-10 ml/kg and colloid of hydroxyethylated starch - 5 ml/kg. On the second days following the donation, epocrine is administered in a single dose 150 units/kg; it is followed with the nutritional supplementation with using enteral mixtures, for cause, parenteral support of protein exchange is applied. On the third day after the first donation, the biochemical analysis of blood serum, the hemostasis system analysis and the complete blood count and clinical urine analysis are used to control the case. The hemoglobin level 110 g/l, and packed cell volume 33% and decreased hemoglobin by 15 g/l and less of the reference level enables to perform the second blood donation. If the reference hemoglobin has decreased by 15 g/l and more, autodonation represents autoplasma giving. On the operation day, the acute normovolemic hemodilution is performed.

EFFECT: method provides the short-term preparation of autoblood components, including the cases of potential latent iron deficiency in the patient, not leading to the failure of adaptive reserves of an organism.

3 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of biotechnology and genetic engineering. Method includes stages of enucleating oocyte of canine family representative with obtaining an enucleated oocyte-recipient, carrying out transfer of nucleus into the enucleated oocyte using a somatic dog cell as a nucleus donor-cell in optimised conditions in such way as to obtain an embryo with a transplanted nucleus and transfer of the embryo with a transplanted nucleus into the oviduct of surrogate mother.

EFFECT: method can be used for breeding outstanding representatives of the canine family, preservation of rare and nearly extinguished species of the canine family representatives, xenotransplantation and modeling of diseases on animals.

13 cl, 2 dwg, 8 tbl, 10 ex

FIELD: medicine.

SUBSTANCE: invention relates to the field of veterinary. Method includes single subcutaneous introduction of vaccine against paraflu-3 and infectious cattle rhinotracheitis dry cultural live in dose 2 ml to cows 1.5 month before delivery. Additionally cows are immunized with Coli-Vac K99 vaccine, intramuscularly, in dose 10 cm3 and 10-15 days after that in dose - 15 cm3. 15-60 minutes after birth 5% glucose solution in dose 1 ml/kg of body weight, 5% ascorbic acid solution in dose 2 ml per animal and intramuscularly 5% unitiole solution in dose 1 ml/10 kg of body weight are simultaneously introduced to newborn calves obtained from said cows.

EFFECT: method contributes to formation of more intense colostral immunity in newborn calves with low viability in comparison with analogues.

12 tbl, 2 ex

FIELD: agriculture.

SUBSTANCE: invention relates to selection and genetics of neat cattle. Method consists in the fact that immune-genetic analysis of 20 days-old animals' blood groups is carried out, when erythrocyte antigens are identified - markers of milk productivity of seven indicators of inherited abilities: antigens-markers of enhanced milk yields - Q, C2, L', L; antigens-markers of enhanced milk yields and milk fat content - C1, R2; antigens-markers of enhanced milk yields, reduced fat content of milk - E; antigens-markers of reduced milk yields, high fat content of milk - B2, G2, O', P', X2, H", U"; antigens-markers of reduced milk yields - S1; antigens-markers of enhanced fat content of milk - G3, B', D', G', B", G", C' U, J; antigens-markers of reduced fat content of milk - A2, P2, U'. Bulls that improve milk productivity and heifers with inherited abilities of higher milk productivity are selected by availability of the following high-valued antigens-markers in animals genotype: milk yields - C2, L', L, Q, milk fat - G3, B', D', G', B", G", C', U, J, milk yields and milk fat - C1, R2.

EFFECT: method makes it possible to increase milk productivity and to improve profitability of milk production.

2 tbl, 1 ex

FIELD: agriculture.

SUBSTANCE: invention relates to poultry breeding. Method includes division of rearing flocks, separately hens and cocks, by live weight onto three categories: light, medium, heavy. The flock is gathered in groups according to 7-11% of cocks per group scheme. The cocks are placed to hens according to a principle of heavy cocks to light hens, light cocks to heavy hens and medium cocks to medium hens.

EFFECT: method allows to increase homogeneity of the flock.

1 tbl, 1 ex

FIELD: chemistry; biochemistry.

SUBSTANCE: invention pertains to biotechnology, animal husbandry and medicine. Proposed is a transgenic animal from the family of bulls which produces in its milk a recombinant human growth hormone in amount of at least 92 ng/ml per month on average. Also disclosed is a method of creating such a transgenic animal which involves cloning the genetic make-up which codes the hGH gene and a beta-casein promoter in an expression vector. Further, there is transfection into fetal somatic cells of cattle, usually fibroblasts, and nuclear transfer into enucleated oocytes of cattle, that way forming transgenic embryos. The invention can be used in animal husbandry and medicine.

EFFECT: invention enables to obtain a large amount of the human growth hormone.

43 cl, 5 dwg, 3 tbl, 9 ex

FIELD: agriculture.

SUBSTANCE: invention relates to the field of genetic engineering and cloning. Transgenic cow is disclosed, having low activity of prion protein as a result of one or several genetically designed mutations. Specified transgenic cows are also genetically modified for expression of xenoantibodies.

EFFECT: as a result of their resistance to prion diseases, such as trembling disease of cattle, such cows are a safe source of human antibodies for use in pharmaceutics and a safe source of agricultural products.

12 cl, 112 dwg, 13 tbl, 19 ex

FIELD: agriculture.

SUBSTANCE: invention refers to the sphere of hog breeding. Method is based on principle of continuous numerical assessment. Method includes assessment of animal development, productivity and quality of breed according to certain scales. Afterwards total score of animal is calculated, using appropriate formula, and a certain class is assigned.

EFFECT: method is universal for animals of various breeds, types, herds, provides for acceleration of selection process by main criteria of productivity.

9 tbl, 2 ex

FIELD: agriculture.

SUBSTANCE: at 220-275 days of pregnancy in cows, doubly with interval of 2-3 minutes, value of arterial systolic and diastolic pressure is measured in the area of caudal artery with application of medical tonometer. If average arterial systolic pressure is identified as more than 120 mm of mercury column and diastolic pressure of more than 80 mm, development of postnatal diseases is predicted.

EFFECT: method is not labour intensive, is highly accurate.

8 tbl, 4 ex

FIELD: agriculture.

SUBSTANCE: method includes introduction of humin fodder additive from peat into ration with content of humic acids in it that makes 10000 mg/l. During the first day, adaptive dose of 0.1 ml per kg of live mass is added once per day, and starting from the third day - in dose of 0.5-0.7 ml.

EFFECT: method makes it possible to increase safety and growth of live mass in pigs at low temperatures.

4 tbl, 5 ex

FIELD: agriculture.

SUBSTANCE: method for growth of piglets includes their keeping in nests together with sow, and after weaning from sow - in groups formed as per their sexual identity. The novelty is the fact that immediately after farrow, all piglets are weaned from sows, number of functioning nipples are identified in sows, new nests of piglets are arranged, with separation of suckling piglets according to sexual identity; and the same time number of boar pigs or gilts in new nests corresponds to number of functioning nipples in sows; after weaning from sows, nests of piglets are combined in groups, which include at least two nests of unisexual piglets.

EFFECT: improved growth of piglets, improvement of their functional activity, achieved as a result of reduction of stress situations in growth of suckling piglets in new unisexual nests, which are arranged immediately after birth of piglets, and as a result of stress situation mitigation as they are transferred for nursery.

2 tbl, 1 dwg, 2 ex

FIELD: animal science.

SUBSTANCE: the present innovation deals with dynamic loading onto cardio-vascular system in animals. Selection should be carried out by the following parameters: , ΔT3 and Δn, where ΔT1 - the time for pulse increase at running, ΔT2 - the time for pulse stabilization after running, ΔT3 - the time for pulse increase after running, Δn - the increase of pulse frequency after running. One should select animals into milking herd at the following values; ΔT3 ≤ 10 sec, Δn ≤ 10 beats/min. The method enables to present perspective evaluation of lactation capacity in animals.

EFFECT: higher efficiency of selection.

1 dwg, 1 ex, 1 tbl